Sat, Dec 27, 2014, 10:15 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Myriad Genetics Inc. Message Board

  • roxettewish roxettewish Dec 30, 2013 8:29 AM Flag

    MYGN going to $15 see article

     

    Myriad Genetics downgraded to Underperform at JMP Securities
    JMP Securities downgraded Myriad Genetics to Underperform from Market Perform after the Centers for Medicare & Medicaid Services said Friday that the BRCA pricing was not a misprint. JMP sees little chance that the prices will revert to the previous level of around $2,900 for code 81211 and set a $15 price target for Myriad shares.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Ok, CMS is practicing medicine by attaching no value to BRCA 2 sequencing. Can they do that? Of course they can. But can they do it without getting their attitude readjusted (look up LART)? That's what is about to play out.

      Nearest parallel that comes to mind is denial of reimbursement for Avastin in breast cancer, but medical consensus had already been reached that its value couldn't be proved.

 
MYGN
36.65+0.15(+0.41%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
Prothena Corporation plc
NASDAQFri, Dec 26, 2014 4:00 PM EST